Economically Viable, Same-Day Autologous Cell Therapies
Link to article
EXUMA Biotech Announces Collaboration with Moffitt Cancer Center for the Development of a Rapid-Point-Of-Care SC CAR-T Program
WEST PALM BEACH, FL., January 11, 2021 – EXUMA Biotech Corp., a clinical-stage biotechnology company discovering and developing chimeric antigen receptor (CAR)-T products and delivery solutions for liquid and solid tumors, announced today that the company has entered into a strategic collaboration with Moffitt Cancer Center to develop EXUMA’s first rapid point-of-care, or “rPOC”, subcutaneous […]
EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care “rPOC” Subcutaneous CAR-T Platform at the SITC 35th Anniversary Annual Meeting & Pre-Conference
WEST PALM BEACH, FL., November 11, 2020 – EXUMA Biotech Corp., a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, today announced that preclinical data for the company’s next-generation rapid point-of-care, or “rPOC”, subcutaneous (SC) autologous CAR-T platform, are being presented today in an e-poster at the […]
Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression
Abstract #117 Link to poster Key Messages: We demonstrate that subcutaneous (SC) delivery of human PBMCs modified by a 4- hour exposure to CD3-directed lentiviruses encoding a CD19 or a CD22 Chimeric Antigen Receptor (CAR) resulted in potent anti-tumor efficacy and robust in vivo expansion of CAR-T positive cells. CAR-T cells driven by a synthetic […]
Logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumors
Link to virtual “poster” presentation Key Messages: The current work describes a high-throughput method for screening lymphoproliferative elements in vivo in a lentivirus format for next generation CAR-T A “logic-gated” HER2-targeted CAR-T was designed that preferentially recognizes HER2 in the tumor microenvironment (TME), thereby limiting on-target toxicity of low HER2 levels expressed in […]
Dr. Sid Kerkar Joins EXUMA Biotech as Vice President Oncology, R&D, Company Presents Data on HER2-Targeting CAR-T at AACR Tumor Immunology and Immunotherapy Conference
WEST PALM BEACH, FL. October 19, 2020- EXUMA Biotech Corporation, a clinical-stage biotechnology company discovering and developing CAR-T products and delivery solutions for liquid and solid tumors, is pleased to announce that Dr. Sid Kerkar, M.D., has joined the company’s senior leadership team as Vice President Oncology, Research & Development effective September 2020. Dr. Kerkar […]
Communicating Your Strategic Plan
Listen to the podcast
Speeding the Delivery of CAR-T Therapies While Cutting the Cost
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Expanding Access to CAR-T: Dr. Greg Frost
“When I started Halozyme in San Diego back in 1999, it spun out of Sidney Kimmel Cancer Center. I used to joke when I left in 2014 that it was the longest postdoc on record. We looked at the technology we were building and saw the pieces that could come together to help some of […]
How Big Data Is Accelerating EXUMA Biotech In The Race To Rapid CAR-T Therapy
“It was at Halozyme where Dr. Frost acquired his penchant for applying speed to large molecule therapy. Now, as Chairman and CEO at EXUMA Biotech, he’s applying that penchant to the administration of cell and gene therapies. That’s a considerably more complicated—and daunting—mission. Reducing the administration time of monoclonal antibodies, for instance, from 8 hours (intravenous) […]
